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pdate on the Molecular Epidemiology of Human
nterovirus 71 in Taiwan Since 1998
.S. Wu ∗, Y.P. Huang, T.L. Lin, L.C. Hsu, C.F. Yang, H.S. Kuo
Centers for Disease Control, Taiwan, Taipei, Taiwan
uman enteroviruses 71 (EV71) is a major causative
athogen of hand, foot and mouth disease (HFMD). Its
nfections caused devastating clinical outcomes in children
orldwide. Most EV71 isolates belong to either genogroups B
r C, which are each further divided into subgenogroups, B1-
5 and C1-C5. In Taiwan, a large EV71 outbreak occurred in
998, followed by two lesser outbreaks in 2000 and 2001,
hich claimed 34, 25, and 26 deaths, respectively. After
hat, Taiwan CDC established a Taiwan Virology Reference
aboratories Network (TVRLN) in 1999 to examine the spec-
mens collected by our sentinel physicians. There were 11,
09, 455, 175, 59, 209, 330, 4, and 16 EV71 strains iso-
ated by TVRLN each year from 1999 to 2007, respectively.
efore that period, all Taiwanese isolates, most obtained
n 1980 and 1986, belonged to genotype B only, whereas
he ones isolated in the 1998 outbreaks turned out to be
ubgenogroup C2 and B4, followed by subgenogroup B4 from
999 to 2003, and subgenogroup C4 from 2004 to 2005. In
006-2007, the major subgenotypes of EV71 circulating in
aiwan changed to C5, and B5. Although, the annual num-
ers of HFMD/herpagina cases conﬁrmed to be due to EV71
nfection dropped dramatically over the last two years, it
eems very likely there is a rising trend of EV71 infections
rom the very beginning of 2008 in Taiwan. As of March 21, as
any as 36 EV71 isolates were conﬁrmed. In conclusion, we
elieve that there is a need for us to monitor them very care-
ully to see if the said two newly emerging subgenogroups
ould create a serious impact on Taiwan public health
ystem.
oi:10.1016/j.ijid.2008.05.077
rug Discovery as a Public Health Intervention: The
vermectin Story (invited)
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rug Discovery as a Public Health Intervention: The
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vermectin is the 22,23-dihydro derivative of avermectin B1,
macrolide produced by an actinomycete, Streptomyces
vermitilis, which we discovered in 1973 in a soil sample
nd later renamed S. avermectinius.
The drug arose from a pioneering international collabora-
ion between my group at The Kitasato Institute in Japan and
he MSD Research Laboratories in the United States. The out-
ome of this alliance led to an important advance in animal
ealth products, through development of an extremely safe
rug with a broad spectrum of antiparasitic activity. After
ntroduction to the market in 1981 as an anthelmintic, iver-
ectin soon proved to be the most effective antiparasitic
t
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rug ever developed and became a ‘blockbuster’ market
eader within two years.
Ivermectin has also provided immeasurable beneﬁts to
uman health for over 20 years, improving the lives of
undred of millions of the world poorest people in the
rocess. Thanks to a pioneering drug donation initiative,
vermectin is being used, free of charge, in global pro-
rammes to eliminate two devastating diseases that mainly
ffect poor communities in developing countries. Both dis-
ases are caused by ﬁlarial worms, onchocerciasis (river
lindness) arising from infection with Onchocerca volvu-
us and lymphatic ﬁlariasis (elephantiasis), one of the most
revalent tropical diseases, resulting from infection with
ither Wuchereria bancrofti or Brugia malayi. Ivermectin
s so safe that tablets can be administered by non-medical
ndividuals from affected communities following one or two
ays training.
Ivermectin is also now being used to treat strongyloidi-
sis, an intestinal parasitic disease widely distributed in
outh-East Asia and the southern Japanese Islands, and to
reat scabies, which is estimated to infect more than 300
illion people globally each year.
Genetic analysis of avermectin biosynthesis and genome
apping of S. avermectinius, and the potential they offer
or development of more effective compounds, will also be
iscussed.
oi:10.1016/j.ijid.2008.05.078
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A-MRSA as a Hospital Pathogen
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here are two epidemics of MRSA: 1) The 30 year old hospital
ssociated strains are increasing in prevalence and escap-
ng to the community with discharged patients, and 2) the
trains from the 10 year old community-associated epidemic
CA-MRSA) have quickly escalated in recent years and now
re entering hospitals. The CA-MRSA isolates are consider-
bly more virulent than the standard health-care associated
nes, perhaps by virtue of the associated toxin- PVL- and
herefore create a serious worry for the clincians. In the last
ecade a number of clusters have been reported in U.S. and
uropean Hospitals of infections with CA-MRSA. The antibi-
grams are different curently among the strains in the two
pidemics, and many challenges await to be addressed:
At what proportion of all S. aureus nosocomial infections
ill perioperative prophylaxis change, will empirical ther-
py for sepsis or ventilator-associated pneumonia in the ICU
hange? How will we identify carriers? Will the outcomes be
ore serious? What options to prevent and treat these CA-
RSA nosocomial infections exist, and what are the adverse
ffects of the antibiotic options?
These are issues that will be addressed in the presenta-
ion.
oi:10.1016/j.ijid.2008.05.079
